Sphingosine kinase inhibitors and cancer: Seeking the golden sword of hercules

Cancer Research

Volumn 71, Issue 21, 2011, Pages 6576-6582

  Pyne, Susan ^a   Bittman, Robert ^b   Pyne, Nigel J ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; FINGOLIMOD; FTY 720 VINYLPHOSPHONATE; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; P21 ACTIVATED KINASE 1; PROHIBITIN; PROHIBITIN 2; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE; SPHINGOSINE KINASE 1; SPHINGOSINE KINASE 1 INHIBITOR; SPHINGOSINE KINASE 2; SPHINGOSINE KINASE 2 INHIBITOR; SPHINGOSINE KINASE INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG;

ALLOSTERISM; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL PROLIFERATION; COMPETITIVE INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; GENE; GENE EXPRESSION; HUMAN; METASTASIS; METASTASIS INHIBITION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SPHINGOSINE KINASE 1 GENE; TUMOR CELL;

ALLOSTERIC REGULATION; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LYSOPHOSPHOLIPIDS; MICE; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROPYLENE GLYCOLS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASE INHIBITORS; SPHINGOSINE; VINYL COMPOUNDS;

EID: 80155127315     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2364     Document Type: Review

References (31)

1. Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nature Rev Cancer 2010;10:489-503.
2. Long JS, Edwards J, Watson C, Tovey S, Mair K, Schiff R, et al. (2010) Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor positive breast cancer cells. Mol Cell Biol 2010;30:3827-41.
3. 3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am J Pathology 2010;177:2205-15.
4. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002;277:21453-7. (Pubitemid 34952287)
5. Tonelli F, Lim KG, Loveridge C, Long J, Pitson SM, Tigyi G, et al. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell Signal 2010;22:1536-42.
6. Ren S, Babelova A, Moreth K, Xin C, Eberhardt W, Doller A, et al. Transforming growth factor-beta2 upregulates sphingosine kinase-1 activity, which in turn attenuates the fibrotic response to TGF-beta2 by impeding CTGF expression. Kidney Int 2009;76:857-67.
7. Kono Y, Nishiuma T, Nishimura Y, Kotani Y, Okada T, Nakamura S, et al. Sphingosine kinase 1 regulates differentiation of human and mouse lung fibroblasts mediated by TGF-beta1. Am J Respir Cell Mol Biol 2007;37:395-404. (Pubitemid 47502714)
8. Jeng YJ, Suarez VR, Izban MG, Wang HQ, Soloff MS. Progesteroneinduced sphingosine kinase-1 expression in the rat uterus during pregnancy and signaling consequences. Am J Physiol Endocrinol Metab 2007;292:E1110-21. (Pubitemid 46536511)
9. Ren S, Xin C, Pfeilschifter J, Huwiler A. A novel mode of action of the putative sphingosine kinase inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole (SKI II): induction of lysosomal sphingosine kinase 1 degradation. Cell Physiol Biochem 2010;26:97-104.
10. Loveridge C, Tonelli F, Leclecq T, Lim KG, Long S, Berdyshev E, et al. The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells. J Biol Chem 2010;285:38841-52.
11. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, et al. Validation of an anti-sphingosine 1-phosphate antibody as a potential therapeutic in reducing growth, invasion and angiogenesis in multiple tumour lineages. Cancer Cell 2006;9:225-38. (Pubitemid 43357948)
12. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, et al. Regulation of histone acetylation in the nucleus by sphingosine 1- phosphate. Science 2009;325:1254-7.
13. Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, et al. Sphingosine 1-phosphate is a missing co-factor for the E3 ligase TRAF2. Nature 2010;465:1084-8.
14. Maceyka M, Alvarez E, Milstien S, Spiegel S. Filamin A links sphingosine kinase 1 and sphingosine-1-phosphate receptor 1 at lamellipodia to orchestrate cell migration. Mol Cell Biol 2008;28: 5687-97.
15. Strub GM, Paillard M, Liang J, Gomez L, Allegood JC, Hait NC, et al. Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration. FASEB J 2011;25: 600-12.
16. Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, et al. Interleukin 6, a nuclear-κB target predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor- κB inhibition by PS-1145 enhances docetaxel anti-tumour activity. Clin Cancer Res 2006;12:5578-86. (Pubitemid 44497276)
17. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003;63:5962-9. (Pubitemid 37187498)
18. French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK, Smith CD. Antitumour activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther 2006;318:596-603. (Pubitemid 44061234)
19. Paugh SW, Paugh BS, Rahmani M, Kapitonov D, Almenara JA, Kordula T, et al. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukaemia. Blood 2008;112: 1382-91.
20. Kapitonov D, Allegood JC, Mitchell C, Hait NC, Almenara JA, Adams JK, et al. Targeting sphingosine kinase 1 inhibits AKT signalling induces apoptosis and suppresses growth of human glioblastoma cells and xenografts. Cancer Res 2009;69:6915-23.
21. French KJ, Zhuang Y, Maines LW, Gao P, Wang W, Beljanski V, Upson JJ, et al. Pharmacology and antitumour activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther 2010;333:129-39.
22. Beljanski V, Knaak C, Smith CD. A novel sphingosine kinase inhibitor induces autophagy in tumour cells. J Pharmacol Exp Ther 2010;333: 454-64.
23. Lim KG, Sun C, Bittman R, Pyne NJ, Pyne S. (R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival ofMCF-7 breast cancer cells. Cell Signal 2011;23: 1590-5.
24. Lim KG, Tonelli F, Li Z, Lu X, Bittman R, Pyne S, et al. FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation and actin rearrangement in MCF-7 breast cancer cells. J Biol Chem 2011;286: 18633-40.
25. Billich A, Bornacin F, Devay P, Mechtcheriakova D, Urtz N, Baumruker T. Phosphorylation of the immunomodulatory drug, FTY720 by sphingosine kinase. J Biol Chem 2003;278:47408-15. (Pubitemid 37523181)
26. Matsuoka Y, Nagahara Y, Ikekita M, Shinomiya T. (2003) A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br J Pharmacol 138;1303-12. (Pubitemid 36543128)
27. Kennedy AJ, Mathews TP, Kharel Y, Field SD,Moyer ML, East JE, et al. Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells. J Med Chem 2011;54:3524-48.
28. Hawinkels LJ, Ten Dijke P. Exploring anti-TGF-β therapies in cancer and fibrosis. Growth Factors 2011;29:140-52.
29. Antoon JW, Meacham WD, Bratton MR, Slaughter EM, Rhodes LV, Ashe HB, et al. Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer. J Mol Endocrinol 2011;46:205-16.
30. Antoon JW,White MD, MeachamWD, Slaughter EM, Muir SE, Elliott S, et al. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology 2010;151:5124-35.
31. Valentine WJ, Kiss GN, Liu J, E S, Gotoh M, Murakami-Murofushi K, et al. (S)-FTY720-vinylphosphonate, an analogue of the immunosuppressive agent FTY720, signals as a pan-antagonist of sphingosine 1- phosphate GPCR and inhibits autotaxin activity. Cell Signal 2010; 22:1543-53.